| Tussle at Hospital Over Corruption Case MediSys, a $1 billion hospital network, is facing new questions about its operations in the wake of an influence-peddling scandal that sent a former Queens assemblyman to prison for six years. online.wsj.com |
Peregrine Pharmaceuticals, Inc. F4Q10 (Qtr End 04/30/10) Earnings Call Transcript Peregrine Pharmaceuticals, Inc. (PPHM)F4Q10 (Qtr End 04/30/10) Earnings CallJune 14, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Arena Pharmaceuticals: The Next Multi-Billion Dollar Biotech? John Tucker submits: Long-suffering Arena Pharmaceutical (ARNA) shareholders are basking in the warm glow of vindication this week. After years of disappointing performance, the company’s share value has more than doubled since June 30. With its lead product candidate Lorcaserin widely dismissed as the least effective of the three obesity drugs currently in late stage development, Arena’s share price actually dropped the day it announced the results of its first successful phase 3 clinical trial. With the events of the last few weeks, Arena’s market capitalization now exceeds that of its competitors by a wide margin (Table 1), and the recent share price trajectory suggests that Arena could become a billion dollar company well in advance of an FDA decision on Lorcaserin. click to enlargeComplete Story » seekingalpha.com |
Will the FDA Give Vivus More Time Before the Final Judgment on Qnexa? David Greene submits:What a conundrum for Vivus (VVUS) and the FDA.Vivus announced last week what I am sure they wish they could have announced prior to the FDA panel meeeting in July--the results of a two year study monitoring 675 obese or overweight patients using the company's Qnexa drug, showing an average weight loss of 11.4 percent with much less threatening side effects than what was presented with the results of a one year study. The one year trial ended up with the Food and Drug Administration panel in July recommending against approving Qnexa due to concerns of negative side effects such as memory lapses, suicidal thoughts, heart palpitations, and birth defects.Complete Story » seekingalpha.com |
Tengion Appoints Richard E. Kuntz, MD to its Board of Directors [PR Newswire] - Tengion Inc. , a leader in regenerative medicine, today announced that it has appointed Richard E. Kuntz, MD, M.Sc., Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of Medtronic, Inc. , to its Board of Directors. us.rd.yahoo.com |